We are live on ! Find out more
XDNA

Strategic Trust Kelly CRISPR & Gene Editing Technology ETF
XDNA

Delisted

XDNA was delisted on the 30th of November, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in Strategic Trust Kelly CRISPR & Gene Editing Technology ETF in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 2 → 0 (-2)

100% less capital invested

Capital invested by funds: $95.8K → $0 (-$95.8K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
–
Holders Change
-2
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
-$92.6K
2
UBS Group
UBS Group
Switzerland
-$3.11K
Name Holding Trade Value Shares
Change 		Change in
Stake
Jane Street
1
Jane Street
New York
– -$92.6K -12,486 Closed
UBS Group
2
UBS Group
Switzerland
– -$3.11K -419 Closed

XDNA Hedge Fund Activity: Q4 2023 in Review

0 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Strategic Trust Kelly CRISPR & Gene Editing Technology ETF (XDNA) for Q4 2023, worth a combined $0 — down 100% from $95.8K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of XDNA and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Jane Street, exiting entirely with an estimated $92.6K sold.

  • 0 institutional investors held Strategic Trust Kelly CRISPR & Gene Editing Technology ETF (XDNA) as of Q4 2023, down from 2 in Q3 2023.
  • Funds reported $0 of Strategic Trust Kelly CRISPR & Gene Editing Technology ETF stock for Q4 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Strategic Trust Kelly CRISPR & Gene Editing Technology ETF positions in Q4 2023 and 2 closed out, a net change of -2 holders.
  • The largest Strategic Trust Kelly CRISPR & Gene Editing Technology ETF seller in Q4 2023 was Jane Street, an estimated $92.6K sold.

Based on aggregated 13F filings for Q4 2023.